Terms: = Leukemia AND IL7R, P16871, IL-7R-alpha, CDW127, CD127, ENSG00000168685, 3575 AND Treatment
56 results:
1. Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.
Lee CH; Hsu KW; Hsieh YY; Li WT; Long Y; Lin CY; Chen SH
Cells; 2024 Apr; 13(7):. PubMed ID: 38607055
[TBL] [Abstract] [Full Text] [Related]
2. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J; Fiskus WC; Daver N; Wilson NR; Ravandi F; Garcia-Manero G; Kadia T; DiNardo CD; Jabbour E; Burger J; Short NJ; Alvarado Y; Jain N; Masarova L; Issa GC; Qiao W; Khoury JD; Pierce S; Miller D; Sasaki K; Konopleva M; Bhalla KN; Borthakur G; Pemmaraju N
Clin Cancer Res; 2023 Nov; 29(21):4352-4360. PubMed ID: 37585491
[TBL] [Abstract] [Full Text] [Related]
3. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Gao XN; Su YF; Li MY; Jing Y; Wang J; Xu L; Zhang LL; Wang A; Wang YZ; Zheng X; Li YF; Liu DH
Cancer Immunol Immunother; 2023 Aug; 72(8):2769-2782. PubMed ID: 37166484
[TBL] [Abstract] [Full Text] [Related]
4. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
5. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract] [Full Text] [Related]
6. Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic leukemia-The State-of-the-Art Knowledge and Future Prospects.
Kośmider K; Karska K; Kozakiewicz A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409154
[TBL] [Abstract] [Full Text] [Related]
7. Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.
Almeida ARM; Neto JL; Cachucho A; Euzébio M; Meng X; Kim R; Fernandes MB; Raposo B; Oliveira ML; Ribeiro D; Fragoso R; Zenatti PP; Soares T; de Matos MR; Corrêa JR; Duque M; Roberts KG; Gu Z; Qu C; Pereira C; Pyne S; Pyne NJ; Barreto VM; Bernard-Pierrot I; Clappier E; Mullighan CG; Grosso AR; Yunes JA; Barata JT
Nat Commun; 2021 Dec; 12(1):7268. PubMed ID: 34907175
[TBL] [Abstract] [Full Text] [Related]
8. Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
Thomas KR; Allenspach EJ; Camp ND; Wray-Dutra MN; Khim S; Zielinska-Kwiatkowska A; Timms AE; Loftus JP; Liggitt HD; Georgopoulos K; Tasian SK; James RG; Rawlings DJ
Leukemia; 2022 Jan; 36(1):42-57. PubMed ID: 34193976
[TBL] [Abstract] [Full Text] [Related]
9. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract] [Full Text] [Related]
10. Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.
Roy U; Raghavan SC
Int J Cancer; 2021 Sep; 149(6):1210-1220. PubMed ID: 33634864
[TBL] [Abstract] [Full Text] [Related]
11. After treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid leukemia.
Delia M; Carluccio P; Mestice A; Frappampina R; Albano F; Specchia G; Musto P
J Immunol Res; 2020; 2020():2134647. PubMed ID: 33204734
[TBL] [Abstract] [Full Text] [Related]
12. Synergism between il7r and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
[TBL] [Abstract] [Full Text] [Related]
13. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Casneuf T; Adams HC; van de Donk NWCJ; Abraham Y; Bald J; Vanhoof G; Van der Borght K; Smets T; Foulk B; Nielsen KC; Rusbuldt J; Axel A; Lysaght A; Ceulemans H; Stevenaert F; Usmani SZ; Plesner T; Avet-Loiseau H; Nijhof I; Mutis T; Schecter JM; Chiu C; Bahlis NJ
Leukemia; 2021 Feb; 35(2):573-584. PubMed ID: 32457357
[TBL] [Abstract] [Full Text] [Related]
14. IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model.
Wang D; Shao Y; Zhang X; Lu G; Liu B
J Transl Med; 2020 Jan; 18(1):23. PubMed ID: 31937346
[TBL] [Abstract] [Full Text] [Related]
15. [Mutation and Clinical Feature of IL-7R in Adult Patients with Acute Lymphoblastic leukemia].
Fu GM; Chen DD; Wu C; Wang M; Pan ZX; Peng XY; Sun H; Sun L; Liu YF; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1416-1423. PubMed ID: 31607292
[TBL] [Abstract] [Full Text] [Related]
16. The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study.
Ronsley R; Kariminia A; Ng B; Mostafavi S; Reid G; Subrt P; Hijiya N; Schultz KR
Pediatr Hematol Oncol; 2019 Nov; 36(8):468-481. PubMed ID: 31530240
[No Abstract] [Full Text] [Related]
17. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
[TBL] [Abstract] [Full Text] [Related]
18. Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Alcantara M; Simonin M; Lhermitte L; Touzart A; Dourthe ME; Latiri M; Grardel N; Cayuela JM; Chalandon Y; Graux C; Dombret H; Ifrah N; Petit A; Macintyre E; Baruchel A; Boissel N; Asnafi V
Blood Adv; 2019 Jul; 3(13):1981-1988. PubMed ID: 31270080
[TBL] [Abstract] [Full Text] [Related]
19. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
20. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid leukemia Who Received Dasatinib as a Second-line treatment.
Okada M; Imagawa J; Tanaka H; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Mizuta S; Hashino S; Nomura T; Shikami M; Fukutani H; Ohe Y; Kosugi H; Shibayama H; Maeda Y; Fukushima T; Yamazaki H; Tsubaki K; Kukita T; Adachi Y; Nataduka T; Sakoda H; Yokoyama H; Okamoto T; Shirasugi Y; Onishi Y; Nohgawa M; Yoshihara S; Morita S; Sakamoto J; Kimura S;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):353-360.e1. PubMed ID: 29610029
[TBL] [Abstract] [Full Text] [Related]
[Next]
